LEXICON
No.146 March 18, 2015

Annual NHI Drug Price Revisions
毎年改定

Japan has been revising NHI drug prices every two years since 1988, except for years with sales tax hikes, based on a recommendation paper issued in 1987 by the Central Social Insurance Medical Council (Chuikyo). The market prices of drugs...

To read the full story

LEXICON

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…